All In Biotech

Drug Trial Radar · NCT06550882

A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea

Post-Marketing Surveillance (Use-result Surveillance) of OBIZUR Injection [Susoctocog Alpha (Porcine Antihemophilic Factor VIII, Recombinant)] for the Approved Indications in South Korea

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

11

Planned (sponsor's estimate)

Start

Jul 22, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Aug 13, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting conditions. People living with AHA can have sudden and severe bleeding. They also have longer bleeding compared to people without AHA. The main aim of the study is to learn how safe OBIZUR is in adults with AHA. Other aims are to see how effective OBIZUR is to control bleeding and how treatment is used in a routine clinical practice setting. The treatment of the participants will be determined by the treating physicians. During the study, data already existing in the participants' medical record and new data will be collected.

Conditions

  • Acquired Hemophilia A

Interventions

  • OBIZURDrug

    OBIZUR injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Causality to AEs, Serious AEs (SAEs) and AEs of Special Interest (AESI)Time frame: Up to 3 months
  2. Number of Participants With Expected/Unexpected AEs and SAEsTime frame: Up to 3 months
  3. Number of Participants With Adverse Drug Reactions (ADRs), Unexpected ADRs, Serious ADRs, Expected SADRs and Unexpected SADRsTime frame: Up to 3 months
  4. Number of Participants With Special Situation Report (SSR)Time frame: Up to 3 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Kyung Hee University Hospital at Gangdong

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea · Recruiting

  • Ewha Womans University Medical Center

    Seoul, South Korea · Recruiting

  • Ulsan University Hospital

    Ulsan, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.